All In Biotech

Drug Trial Radar · NCT00343460

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 1,428 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,428

Actual

Start

Jun 2006

Primary completion

Sep 2008

Study completion Feb 2009

Sponsor

Lead sponsor
Heron TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 23, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.

Conditions

  • Nausea and Vomiting
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

  • APF530Drug

    Given subcutanously

  • dexamethasoneDrug

    Given IV and orally

  • Palonosetron HydrochlorideDrug

    Given IV

  • placeboOther

    Given subcutanously or IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1Time frame: 0-24 Hours
  2. Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1Time frame: 24-120 Hours

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • Anniston Oncology, PC

    Anniston, Alabama

  • Palo Verde Hematology Oncology - Glendale

    Glendale, Arizona

  • Arizona Clinical Research Center, Incorporated

    Tucson, Arizona

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Pacific Cancer Medical Center, Incorporated

    Anaheim, California

  • Southbay Oncology / Hematology Medical Group

    Campbell, California

  • Compassionate Cancer Care Medical Group Incorporated - Corona

    Corona, California

  • Compassionate Cancer Care Medical Group Incorporated - Fountain Valley

    Fountain Valley, California

  • Advanced Research Management Services, Incorporated

    Los Angeles, California

  • Kenmar Research Institute

    Los Angeles, California

  • Medical Oncology Care Associates - Orange

    Orange, California

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut

  • Providence Hospital

    Washington D.C., District of Columbia

  • Pasco Pinellas Cancer Center - New Port Richey

    New Port Richey, Florida

  • Innovative Medical Research of South Florida, Incorporated

    North Miami Beach, Florida

  • Columbus Clinic, PC

    Columbus, Georgia

  • Clintell, Incorporated

    Skokie, Illinois

  • Investigative Clinical Research, LLC

    Indianapolis, Indiana

  • Cancer Center of Indiana

    New Albany, Indiana

  • Family Medicine of Vincennes Clinical Trial Center

    Vincennes, Indiana

  • Medical Center Vincennes

    Vincennes, Indiana

  • Kentucky Cancer Clinic - Hazard

    Hazard, Kentucky

  • Kentuckiana Cancer Institute, PLLC

    Louisville, Kentucky

  • Hematology-Medical Oncology Associates at Central Maine Comprehensive Cancer Center

    Lewiston, Maine

  • Mercy Medical Center

    Baltimore, Maryland

  • Center for Cancer and Blood Disorders at Suburban Hospital

    Bethesda, Maryland

  • Center for Clinical Research at Washington County Hospital

    Hagerstown, Maryland

  • Northern Michigan Hospital

    Petoskey, Michigan

  • Regional Cancer Center at Singing River Hospital

    Pascagoula, Mississippi

  • Kansas City Cancer Centers - South

    Kansas City, Missouri

  • Star Hematology & Oncology

    Phillipsburg, New Jersey

  • Veterans Affairs Medical Center - Buffalo

    Buffalo, New York

  • Falck Cancer Center at Arnot Ogden Medical Center

    Elmira, New York

  • Hudson Valley Hematology-Oncology Associates - Poughkeepsie

    Poughkeepsie, New York

  • Comprehensive Cancer Center at Pardee Hospital

    Hendersonville, North Carolina

  • Boice Willis Clinic, PA

    Rocky Mount, North Carolina

  • Eastern North Carolina Medical Group, PLLC

    Rocky Mount, North Carolina

  • McDowell Cancer Center at Akron General Medical Center

    Akron, Ohio

  • Gabrail Cancer Center - Canton Office

    Canton, Ohio

  • Gabrail Cancer Center - Dover Office

    Dover, Ohio

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.